Zapping the brain to calm dementia agitation
NCT ID NCT03846492
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores how non-invasive brain stimulation can help understand and treat agitation in people with Alzheimer's and mixed dementia. Researchers will use transcranial magnetic stimulation (TMS) and electroencephalography (EEG) to study brain activity, and test whether transcranial direct current stimulation (tDCS) can reduce agitation. The study involves 90 participants, including those with and without agitation, plus healthy volunteers.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- transcranial direct current stimulation (tDCS)
- What this could lead to
- If successful, this could point toward a safe, non-drug treatment for agitation in dementia, improving quality of life for patients and caregivers.
- What could go wrong
- This is an early-stage study focused on understanding brain mechanisms, not a proven treatment. The sample is small (90 people), and results may not apply to all dementia patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2019
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Participants with AD+Agitation Inclusion: 1. Age 50 years or older. 2. Participant or substitute decision maker able and willing to provide informed consent. 3. Dementia due to probable or possible AD as defined by NIA-AA criteria. 4. Presence of mild to moderate agitation and/or aggression as defined by: Agitation in cognitive disorders. International Psychogeriatric Association Provisional Consensus Clinical and Research Definition. 5. Availability of a support person to accompany the participant to study appointments and provide collateral information as needed. 6. If taking medication for neuropsychiatric symptoms, the dose should be stable for at least 1 week. Exclusion: 1. Psychiatric diagnosis other than dementia significantly impacting the presentation. 2. Presence of delirium or other acute medical condition significantly contributing to agitation/aggression or making the study participation unsafe for a participant. 3. Any contraindication to TMS or tDCS. 4. Any other condition that in the opinion of principal investigator will make the study participation unsafe or non-feasible for the participant. 5. Currently taking anticonvulsants or benzodiazepines at a dose sufficient to cause interference with TMS-EEG. Participants with AD without aggression All the above inclusion/exclusion criteria except meeting the inclusion criterion 4 pertaining to agitation/aggression. Participants with significant agitation/aggression will be excluded from this group. Healthy comparator participants Inclusion: 1. Age 50 years or older. 2. Able and willing to provide informed consent. 3. Free from any significant neurological disorder. Exclusion: 1. Lifetime DSM-5 diagnosis other than simple phobias or adjustment disorder. 2. Any Contraindication to TMS. 3. Currently taking anticonvulsants or benzodiazepines at a dose sufficient to cause interference with TMS-EEG.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
Toronto, Ontario, M6J 1H4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- A simple gel meets the Mouth's microscopic zoo
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Can a Phone-Based sleep program help dementia caregivers rest better?